Figure 1: A side-by-side comparison of the inflammatory process in a cutaneous setting. Several advantages are evident in the work of Thepen and colleagues 1. By targeting a receptor that is ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

The melanocortin 1 receptor (MC1R or alpha melanocytestimulating ... that numerous MC1R gene variants predisposed individuals to cutaneous melanoma. In stratified analyses, the genetic ...

Researchers investigate the cellular and molecular mechanisms through which stress exacerbates immunoglobulin E cutaneous allergic inflammation.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

About Cutaneous Squamous Cell Carcinoma Cutaneous ... binds PD-L1 and blocks the interaction between PD-L1 and its T cell receptors, PD-1 and B7.1. This interaction releases the inhibitory effects ...

A novel topical gel, HT-001, shows promise as a treatment for cutaneous side effects caused by epidermal growth factor receptor inhibitor (EGFRi) cancer therapy. According to a press release ...

The FDA has approved Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl), a PD-L1 blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell ... rather than programmed ...